Dragnev et al. reported that KRAS-driven lung cancer, which usually responds poorly to the epidermal growth factor receptor (EGFR) inhibitor erlotinib, was particularly dependent on CDK4 and was sensitive to the cyclin D1-degrading combination of bexarotene and erlotinib [57]. Here, KRAS is linked to lung carcinoma.